Morgan Stanley raises Avanos Medical (AVNS) price target to $ 60.00



Avanos Medical (NYSE: AVNS) had raised his price target by Morgan Stanley from $ 58.00 to $ 60.00 in a report released on Wednesday, August 8th. The company currently has an underweight in the shares.

Apart from that, KeyCorp increased their price target at Avanos Medical from $ 66.00 to $ 75.00 and gave the company an overweight rating in a report on Wednesday, August 8th.

NYSE AVNS opened Wednesday at $ 72.29. The company has a market capitalization of $ 3.38 billion, a P / E ratio of 30.76 and a beta of 1.60. Avanos Medical has a 12-month low of $ 41.51 and a 12-month high of $ 72.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.48 and a quick ratio of 2.18.

An institutional investor recently bought a new position in the shares of Avanos Medical. Government officials Retirement System of Ohio acquired a new stake in Avanos Medical Inc. (NYSE: AVNS) in the second quarter, according to the most recent 13F application to the Securities and Exchange Commission (SEC). The institutional investor acquired 2,372 shares of the company's shares, valued at approximately $ 136,000. 89.91% of the shares are held by institutional investors and hedge funds.

Avanos Medical Company profile

Avanos Medical, Inc. operates as a medical technology company focused on eliminating pain, accelerating recovery and preventing infection for healthcare professionals and patients worldwide. The Medical Devices segment offers a portfolio of products that focus on the health of the airways and digestion, alongside surgical and interventional pain management.

Recommended story: Asset allocation

Receive news and ratings for Avanos Medical Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Avanos Medical and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

Morgan Stanley raises Avanos Medical (AVNS) price target to $ 60.00



Avanos Medical (NYSE: AVNS) had raised his price target by Morgan Stanley from $ 58.00 to $ 60.00 in a report released on Wednesday, August 8th. The company currently has an underweight in the shares.

Apart from that, KeyCorp increased their price target at Avanos Medical from $ 66.00 to $ 75.00 and gave the company an overweight rating in a report on Wednesday, August 8th.

NYSE AVNS opened Wednesday at $ 72.29. The company has a market capitalization of $ 3.38 billion, a P / E ratio of 30.76 and a beta of 1.60. Avanos Medical has a 12-month low of $ 41.51 and a 12-month high of $ 72.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.48 and a quick ratio of 2.18.

An institutional investor recently bought a new position in the shares of Avanos Medical. Government officials Retirement System of Ohio acquired a new stake in Avanos Medical Inc. (NYSE: AVNS) in the second quarter, according to the most recent 13F application to the Securities and Exchange Commission (SEC). The institutional investor acquired 2,372 shares of the company's shares, valued at approximately $ 136,000. 89.91% of the shares are held by institutional investors and hedge funds.

Avanos Medical Company profile

Avanos Medical, Inc. operates as a medical technology company focused on eliminating pain, accelerating recovery and preventing infection for healthcare professionals and patients worldwide. The Medical Devices segment offers a portfolio of products that focus on the health of the airways and digestion, alongside surgical and interventional pain management.

Recommended story: Asset allocation

Receive news and ratings for Avanos Medical Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Avanos Medical and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

Leave a Reply